Targeted downregulation of platelet CLEC-2 occurs through Syk-independent internalization

Blood

Volumn 125, Issue 26, 2015, Pages 4069-4077

  Lorenz, Viola ^a   Stegner, David ^a   Stritt, Simon ^a   Vögtle, Timo ^a   Kiefer, Friedemann ^b   Witke, Walter ^c   Schymeinsky, Jürgen ^d   Watson, Steve P ^e   Walzog, Barbara ^d   Nieswandt, Bernhard ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b MAX PLANCK INSTITUTE FOR MOLECULAR BIOMEDICINE   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C TYPE LECTIN LIKE RECEPTOR 2; LEPTIN RECEPTOR; PROTEIN KINASE SYK; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; CLEC-2 PROTEIN, MOUSE; LECTIN; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FETUS; INTERNALIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY; THROMBOCYTE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; BLOTTING, WESTERN; DOWN-REGULATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LECTINS, C-TYPE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLATELET ACTIVATION; PROTEIN-TYROSINE KINASES; THROMBOCYTOPENIA;

EID: 84933557671     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-11-611905     Document Type: Article

References (41)

1. Jackson SP. Arterial thrombosis-insidious, unpredictable and deadly. Nat Med. 2011;17(11):1423-1436.
2. Nieswandt B, Pleines I, Bender M. Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke. J Thromb Haemost. 2011;9(suppl 1):92-104.
3. Conti CR, Mehta JL. Acute myocardial ischemia: role of atherosclerosis, thrombosis, platelet activation, coronary vasospasm, and altered arachidonic acid metabolism. Circulation. 1987;75(6 Pt 2):V84-V95.
4. Stegner D, Haining EJ, Nieswandt B. Targeting glycoprotein VI and the immunoreceptor tyrosinebased activation motif signaling pathway. Arterioscler Thromb Vasc Biol. 2014;34(8):1615-1620.
5. Colonna M, Samaridis J, Angman L. Molecular characterization of two novel C-type lectin-like receptors, one of which is selectively expressed in human dendritic cells. Eur J Immunol. 2000;30(2):697-704.
6. Suzuki-Inoue K, Fuller GL, García A, et al. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood. 2006;107(2):542-549.
7. Séverin S, Pollitt AY, Navarro-Nuñez L, et al. Sykdependent phosphorylation of CLEC-2: a novel mechanism of hem-immunoreceptor tyrosinebased activation motif signaling. J Biol Chem. 2011;286(6):4107-4116.
8. Bertozzi CC, Schmaier AA, Mericko P, et al. Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling. Blood. 2010;116(4):661-670.
9. Suzuki-Inoue K, Inoue O, Ding G, et al. Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. J Biol Chem. 2010;285(32):24494-24507.
10. Finney BA, Schweighoffer E, Navarro-Núñez L, et al. CLEC-2 and Syk in the megakaryocytic/platelet lineage are essential for development. Blood. 2012;119(7):1747-1756.
11. Hess PR, Rawnsley DR, Jakus Z, et al. Platelets mediate lymphovenous hemostasis to maintain blood-lymphatic separation throughout life. J Clin Invest. 2014;124(1):273-284.
12. Bénézech C, Nayar S, Finney BA, et al. CLEC-2 is required for development and maintenance of lymph nodes. Blood. 2014;123(20):3200-3207.
13. Herzog BH, Fu J, Wilson SJ, et al. Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2. Nature. 2013;502(7469):105-109.
14. Jurasz P, Alonso-Escolano D, Radomski MW. Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol. 2004;143(7):819-826.
15. Kato Y, Kaneko MK, Kunita A, et al. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci. 2008;99(1):54-61.
16. Nakazawa Y, Takagi S, Sato S, et al. Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies. Cancer Sci. 2011;102(11):2051-2057.
17. May F, Hagedorn I, Pleines I, et al. CLEC-2 is an essential platelet-activating receptor in hemostasis and thrombosis. Blood. 2009;114(16):3464-3472.
18. Bender M, May F, Lorenz V, et al. Combined in vivo depletion of glycoprotein VI and C-type lectinlike receptor 2 severely compromises hemostasis and abrogates arterial thrombosis in mice. Arterioscler Thromb Vasc Biol. 2013;33(5):926-934.
19. Navarro-Núñez L, Langan SA, Nash GB, Watson SP. The physiological and pathophysiological roles of platelet CLEC-2. Thromb Haemost. 2013;109(6):991-998.
20. Boulaftali Y, Hess PR, Getz TM, et al. Platelet ITAM signaling is critical for vascular integrity in inflammation. J Clin Invest. 2013;123(2):908-916.
21. Tiedt R, Schomber T, Hao-Shen H, Skoda RC. Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. Blood. 2007;109(4):1503-1506.
22. Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell. 1994;76(3):519-529.
23. Nieswandt B, Moser M, Pleines I, et al. Loss of talin1 in platelets abrogates integrin activation, platelet aggregation, and thrombus formation in vitro and in vivo. J Exp Med. 2007;204(13):3113-3118.
24. Deppermann C, Cherpokova D, Nurden P, et al. Gray platelet syndrome and defective thromboinflammation in Nbeal2-deficient mice [published online ahead of print July 1, 2013]. J Clin Invest.
25. Bender M, Stritt S, Nurden P, et al. Megakaryocyte-specific Profilin1-deficiency alters microtubule stability and causes a Wiskott-Aldrich syndrome-like platelet defect. Nat Commun. 2014;5:4746.
26. Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity. 2006;24(1):19-28.
27. Bergmeier W, Schulte V, Brockhoff G, Bier U, Zirngibl H, Nieswandt B. Flow cytometric detection of activated mouse integrin alphaIIbbeta3 with a novel monoclonal antibody. Cytometry. 2002;48(2):80-86.
28. Königsberger S, Prodöhl J, Stegner D, et al. Altered BCR signalling quality predisposes to autoimmune disease and a pre-diabetic state. EMBO J. 2012;31(15):3363-3374.
29. Luo FR, Yang Z, Camuso A, et al. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res. 2006;12(23):7180-7186.
30. Gratacap MP, Martin V, Valéra MC, et al. The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood. 2009;114(9):1884-1892.
31. Gitz E, Pollitt AY, Gitz-Francois JJ, et al. CLEC-2 expression is maintained on activated platelets and on platelet microparticles. Blood. 2014;124(14):2262-2270.
32. Nieswandt B, Schulte V, Bergmeier W, et al. Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med. 2001;193(4):459-469.
33. Boylan B, Chen H, Rathore V, et al. Anti-GPVIassociated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface. Blood. 2004;104(5):1350-1355.
34. Rabie T, Varga-Szabo D, Bender M, et al. Diverging signaling events control the pathway of GPVI down-regulation in vivo. Blood. 2007;110(2):529-535.
35. Schulte V, Rabie T, Prostredna M, Aktas B, Grüner S, Nieswandt B. Targeting of the collagenbinding site on glycoprotein VI is not essential for in vivo depletion of the receptor. Blood. 2003;101(10):3948-3952.
36. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosomepositive leukemias. N Engl J Med. 2006;354(24):2531-2541.
37. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305(5682):399-401.
38. Tokarski JS, Newitt JA, Chang CY, et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006;66(11):5790-5797.
39. Agarwal N, Di Lorenzo G, Sonpavde G, Bellmunt J. New agents for prostate cancer. Ann Oncol. 2014;25(9):1700-1709.
40. Borgognone A, Navarro-Núñez L, Correia JN, et al. CLEC-2-dependent activation of mouse platelets is weakly inhibited by cAMP but not by cGMP. J Thromb Haemost. 2014;12(4):550-559.
41. Myers MD, Sosinowski T, Dragone LL, et al. Src-like adaptor protein regulates TCR expression on thymocytes by linking the ubiquitin ligase c-Cbl to the TCR complex. Nat Immunol. 2006;7(1):57-66.